Pharmaceutical sponsor
Genrix (Shanghai) Biopharmaceutical Co., Ltd. Clinical Trials
Studies where Genrix (Shanghai) Biopharmaceutical Co., Ltd. is the lead sponsor: its pipeline by phase, what is enrolling now and where. Studies it supports as a collaborator are in the search.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 10Multiple Dose, Healthy Adult Participants
A Clinical Trial of Multiple Doses of GR2301 Injection in Healthy Adult Trial Participants in China.
This is a randomized, double-blind, placebo-controlled Phase I clinical trial evaluating the safety, tolerability, pharmacokinetics and immunogenicity characteristics of GR2301 injection in healthy adult subjects in China.
- Trial name
- NCT07647224
- Testing
- GR2301 injection
- Where
- China
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Vitiligo
A Clinical Trial of Multiple Doses of GR2301 Injection Combined With Phototherapy in Trial Participants With Vitiligo
This is a randomized, double-blind, placebo-controlled Phase Ib/II clinical trial of multiple subcutaneous injections of GR2301 in combination with phototherapy to evaluate the tolerability, safety, pharmacokinetics, and…
- Trial name
- GREVIT (NCT07647237)
- Testing
- GR2301 injection
- Volunteers
- 116 people
- Sponsor
- Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Multiple Myeloma
A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to compare the efficacy of GR1803 Injection with daratumumab in combination with pomalidomide and dexamethasone (DPd).
- Trial name
- NCT07452198
- Testing
- GR1803 injection, Daratumumab, Pomalidomide
- Where
- China
- Volunteers
- 358 people
- Sponsor
- Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Systemic Lupus Erthematosus, Auto Immune Disease
A Study of GR1803 in Systemic Lupus Erythematosus
to evaluate the safety and efficacy of GR1803 in the treatment of patients with systemic lupus erythematosus
- Trial name
- NCT07348055
- Testing
- GR1803 injection
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Health Adult Subjects
A Study to Evaluate the Safety, Immunogenicity, and Pharmacokinetics of GR2303 in Healthy Adult
he goal this clinical trail is to evaluate the safety、Pharmacokinetic and immunogenicity of GR2303 injection。 Subjects will be enrolled in different groups in sequential order, and within each group will be randomly assigned to…
- Trial name
- NCT07199270
- Testing
- GR2303 injection
- Where
- China
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Allergic Rhinitis, Seasonal
A Study of GR1802 Injection in Patients With Seasonal Allergic Rhinitis.
Allergic rhinitis (AR) is a non-infectious chronic inflammatory disease of the nasal mucosa mainly mediated by immunoglobulin E after exposure to allergens in atopic individuals.
- Trial name
- NCT07199257
- Testing
- GR1802 injection
- Where
- China
- Volunteers
- 144 people
- Sponsor
- Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Single Ascending Dose, Healthy Subjects
A Study to Evaluate the Safety of GR2301 Injection in Healthy Volunteers.
This is a randomized, double-blind, placebo-controlled Phase I clinical trial evaluating the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary pharmacodynamic characteristics of GR2301 injection in healthy…
- Trial name
- NCT07190716
- Testing
- GR2301 injection
- Where
- China
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Allergic Rhinitis, Seasonal
A Study of IL4Rα Monoclonal Antibody in Patients With Seasonal Allergic Rhinitis
Allergic rhinitis (AR) is a non-infectious chronic inflammatory disease of the nasal mucosa mainly mediated by immunoglobulin E after exposure to allergens in atopic individuals.
- Trial name
- NCT07154342
- Testing
- GR1802 injection
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Multiple Myeloma
A Study of GR1803 Injection in Combination With Anti-CD38 Monoclonal Antibody for the Treatment of Participants With Multiple Myeloma
The purpose of this study is to identify recommended Phase 3 doses (RP3D) for treatment combination (GR1803 injection plus anti-CD38 monoclonal antibody) and to characterize the efficacy of RP3D for the treatment combination.
- Trial name
- NCT07090954
- Testing
- GR1803 injection, Anti-CD38 Monoclonal Antibody
- Where
- 2 sites in China
- Volunteers
- 32 people
- Sponsor
- Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Multiple Myleoma
GR1803 Injection in Patients With RRMM
All subjects will receive GR1803 injection until intolerable toxicity or investigator-assessed disease progression occurs (except in cases of disease progression due to discontinuation of the drug as a result of an adverse event)…
- Trial name
- NCT06952075
- Testing
- GR1803
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Genrix (Shanghai) Biopharmaceutical Co., Ltd.